GARDP’s 2019 Activity Report shows remarkable progress and promise in the fight against drug-resistant infections. It also demonstrates why more partnerships and investment are needed if we are to address the scourge of antibiotic resistance and achieve Sustainable Development Goal 3: Ensure healthy lives and promote well-being for all.
The Global Antibiotic Research and Development Partnership (GARDP) strategy is a five-year road map for delivering new and improved treatments for drug-resistant infections. The strategy sets out priorities for how our partnership can deliver treatments for the infections posing the greatest threat to health and make those treatments sustainably and responsibly available to every person who needs them.
A report on discussions and outcomes of the Sustainable Access workshop organised by the Global Antibiotic Research and Development Partnership (GARDP) in collaboration with Medicine Patents Pool and the World Health Organization.
2018 has been a landmark year for GARDP. We have built on last year’s successes and made significant progress in addressing Gram-negative drug-resistant infections in children, newborns with sepsis, and sexually-transmitted infections.
The work we have done this year includes conducting three clinical trials and preparing to launch our first phase III clinical trial for a potential new treatment for gonorrhoea. Our discovery and exploratory research, and memory recovery and asset evaluation programme, which has evaluated over 80 assets, gives us the flexibility to expand our current portfolio.
As the first financial year ends on 31 December 2019, the attached interim financial report represents the combined financial statements and activities GARDP carried out in DNDi and the GARDP Foundation in 2018 and are presented on a proforma basis.
During its first full year in operation, GARDP developed a business plan that articulates a seven-year roadmap, prioritizing sepsis in newborns and STIs – two disease areas of high global public health need on which to focus our R&D efforts. Our plans for 2018 are even more ambitious. These include: starting a global observational study, […]